Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q3 2026
Lexicon Pharmaceuticals (LXRX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Lexicon Pharmaceuticals (LXRX) reported revenue of $11.2M for the third quarter 2026 (Q3 2026), -21% from a year earlier and up 16-fold from the quarter before. Operating margin was -128.8%, net loss $14.0M (124.5% of revenue).
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.2M | 16× | -21% |
| Operating profit | −$14.5M | — | — |
| Net earnings | −$14.0M | — | — |
| Operating cash flow | −$8.1M | — | — |
What changed
Revenue was $11.2M in Q3 2026, down 21% year over year and up 1526% from the previous quarter.
Operating costs exceeded revenue by $14.5M, an operating margin of -128.8%. Total costs fell 2% while revenue fell 21%. The fastest-growing cost line was Cost of revenue (+690%). The quarter ended with a net loss of $14.0M, narrower than the previous quarter's $31.8M loss.
Operating cash flow was −$8.1M. Non-cash charges added back $95K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items added $2.4M.
Questions
What was Lexicon Pharmaceuticals' revenue in the third quarter 2026?
Lexicon Pharmaceuticals (LXRX) reported revenue of $11.2M for the third quarter 2026 (Q3 2026), -21% from a year earlier and up 16-fold from the quarter before.
Was Lexicon Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $14.5M (-128.8% of revenue) and net loss $14.0M.